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Though cases of ischemic arterial thrombosis due to
hypercoagulability caused by hyperhomocysteinemia (CVT)
have been reported 1 cerebral venous thrombosis due to
hyperhomocysteinemia is a rarely reported cause of
venous strokes.

His diplopia resolved. After 3 or 4 days, he developed
vomiting, drowsiness and staggering gait.
On the day of admission, the patient had a seizure for
which he was brought to the hospital. Examination, except
for drowsiness, was unremarkable. MRI brain showed an
ischemic lesion in the right parietal cortex with gyriform
enhancement suggestive of venous cortical infarction. MR
venogram showed irregular defect in the superior sagittal
sinus suggestive of cerebral venous thrombosis and partial
recanalization.

Elevated level of homocysteine is strongly associated with
premature arterial or venous thromboembolism. Factors
related with the pathogenesis of venous thrombosis
include blood stasis, hypercoagulability, and vessel
damage. Increa sed thromboembolic risk has been
attributed to antithrombin III, protein C, or protein S
deficiencies as well as factor V Leiden, prothrombin
mutation G20210A, or hyperhomocysteinemia.2

EEG, a repeat lumbar puncture, echocardiogram, routine
c hemi st ri es, blo od c oun ts, pr ot e in C, p rote in S,
antithrombin III, and Factor V Leiden were normal. The
blood cultures and antiphospholipid antibodies were
negative. Plasma homocysteine level was 20.52 µmol/l
(normal reference value 4.45-12.42 µmol/l).

A more recent study demonstrated that elevation of
pl a sma f ac to r V III le ve l pr ove d to b e th e mo st
prothrombotic risk factor for cerebral venous thrombosis
(CVT).3

The patient was treated with heparin infusion (intravenous)
and a PTT was maintained around twice that of normal.
He was also started on folic acid. His symptoms resolved
over a week and he was discharged on warfarin and folic
acid.

We re port tw o c as es of young males, without any
signif icant id en tif iab le ris k for hyp erco agulability,
presenting with headaches, seizures and altered mental
status, who were found to have cortical venous sinus
thrombosis. During workup of hypercoagulable state,
these patients were found to have hyperhomocysteinemia,
a rare cause of venous thrombosis.

CASE 2
A 37 year-old male with a history of diabetes mellitus
presented to ER with new onset of headaches, seizures
and altered mental status.

CASE 1
A 23 year-old male developed symptoms of persistent
diffuse headaches for about a month. He took different
'over-the-counter' medications. His symptoms improved
completely. About a week prior to his admission to the
hospital, he developed double vision. CT scan of the head
and lumbar puncture were normal. He was treated with
oral steroids.
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On initial examination, the patient was drowsy. An urgent
plain CT scan of brain revealed left parieto-occipital
hemorrhage. An emergent cerebral angiogram showed
thrombosis of the superior sagittal sinus, the confluence,
the left transverse sinus and right transverse sinus.
Further workup revealed normal protein C, protein S,
antithrombin III and factor V Leiden. The antiphospholipid
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antibodies were also negative. However, the plasma
homocysteine levels were elevated i.e. 20.17 µmol/l
(4.45-12.42 µmol/l).

CONCLUSION
The two reported cases in our study had moderately
elevated homocysteine level. These patients did not have
other risks for CVT. These cases had almost similar
presentations. Both showed good improvement with
treatment on long-term folate replacement. Further
studies are required to analyze the importance of checking
homocysteine level in cases of CVT, especially where a
clear risk factor has not been identified.

During hospital stay, the patient deteriorated and required
craniotomy and removal of the clot. After the surgery, he
showed dramatic improvement.

DISSCUSION
Cerebral venous thrombosis is a diagnostic challenge due
to its nonspecific symptoms and its relative infrequency.
This is probably more common for underdeveloped
countries where investigations are not readily available.
Even when diagnosed, the cause sometimes remains
elusive.
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High levels of auto-oxidation of homocysteine reacting with
highly reactive oxygen species cause lipid peroxidation
which in turn leads to vascular matrix damage and smooth
muscle cell proliferation leading to atherogenesis. The
same phenomenon also causes vascular endothelial injury
and is responsible for prothrombogenesis.
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